Teladoc Health (TDOC) Expected to Announce Quarterly Earnings on Wednesday

Teladoc Health (NYSE:TDOC) is expected to be posting its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect Teladoc Health to post earnings of ($0.32) per share and revenue of $619.38 million for the quarter. Teladoc Health has set its Q1 2025 guidance at -0.400–0.150 EPS and its FY 2025 guidance at -1.100–0.500 EPS.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The business had revenue of $640.49 million during the quarter, compared to analysts’ expectations of $639.44 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Price Performance

TDOC opened at $7.16 on Tuesday. The stock has a fifty day moving average of $8.38 and a 200-day moving average of $9.56. The firm has a market capitalization of $1.25 billion, a P/E ratio of -1.24 and a beta of 1.73. Teladoc Health has a 12-month low of $6.35 and a 12-month high of $15.21. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66.

Insider Transactions at Teladoc Health

In other Teladoc Health news, insider Adam C. Vandervoort sold 11,011 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total value of $92,712.62. Following the sale, the insider now owns 64,308 shares of the company’s stock, valued at $541,473.36. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.58% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Jefferies Financial Group reduced their target price on Teladoc Health from $10.00 to $8.00 and set a “hold” rating for the company in a report on Monday, April 21st. Royal Bank of Canada increased their price objective on Teladoc Health from $11.00 to $12.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Oppenheimer cut their price objective on Teladoc Health from $14.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, January 24th. Piper Sandler cut their price objective on Teladoc Health from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Finally, Bank of America cut their price objective on Teladoc Health from $9.50 to $8.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Twelve investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.71.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.